Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Bioorg Med Chem Lett ; 22(24): 7672-6, 2012 Dec 15.
Artículo en Inglés | MEDLINE | ID: mdl-23141913

RESUMEN

Amido-1,3,4-thiadiazoles have been identified as a novel structural class of potent and selective sphingosine-1-phosphate receptor subtype 1 agonists. Starting from a micromolar HTS hit with the help of an in-house homology model, robust structural-activity relationships were developed to yield compounds with good selectivity and excellent in vivo efficacy in rat models.


Asunto(s)
Descubrimiento de Drogas , Receptores de Lisoesfingolípidos/agonistas , Tiadiazoles/farmacología , Administración Oral , Animales , Cristalografía por Rayos X , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Encefalomielitis Autoinmune Experimental/tratamiento farmacológico , Linfopenia/sangre , Modelos Moleculares , Estructura Molecular , Ratas , Receptores de Esfingosina-1-Fosfato , Relación Estructura-Actividad , Tiadiazoles/administración & dosificación , Tiadiazoles/síntesis química
2.
Open Forum Infect Dis ; 9(7): ofac216, 2022 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-35794931

RESUMEN

Immunoglobulin (Ig)G medicinal products manufactured in 2020 were tested for infectivity neutralization and hemagglutination inhibition against World Health Organization-selected influenza strains included in worldwide vaccines 2020-2022. The IgG batches (from US plasma) showed potent activity. Intravenous immunoglobulin could potentially add to therapies for serious influenza cases in immunocompromised patients. Further study is warranted.

3.
PLoS One ; 13(1): e0189247, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29320511

RESUMEN

Thymic stromal lymphopoietin (TSLP) is a cytokine released by human lung epithelium in response to external insult. Considered as a master switch in T helper 2 lymphocyte (Th2) mediated responses, TSLP is believed to play a key role in allergic diseases including asthma. The aim of this study was to use a phenotypic approach to identify new biological and chemical starting points for inhibition of TSLP production in human bronchial epithelial cells (NHBE), with the objective of reducing Th2-mediated airway inflammation. To this end, a phenotypic screen was performed using poly I:C / IL-4 stimulated NHBE cells interrogated with a 44,974 compound library. As a result, 85 hits which downregulated TSLP protein and mRNA levels were identified and a representative subset of 7 hits was selected for further characterization. These molecules inhibited the activity of several members of the MAPK, PI3K and tyrosine kinase families and some of them have been reported as modulators of cellular phenotypic endpoints like cell-cell contacts, microtubule polymerization and caspase activation. Characterization of the biological profile of the hits suggested that mTOR could be a key activity involved in the regulation of TSLP production in NHBE cells. Among other targeted kinases, inhibition of p38 MAPK and JAK kinases showed different degrees of correlation with TSLP downregulation, while Syk kinase did not seem to be related. Overall, inhibition of TSLP production by the selected hits, rather than resulting from inhibition of single isolated targets, appeared to be due to a combination of activities with different levels of relevance. Finally, a hit expansion exercise yielded additional active compounds that could be amenable to further optimization, providing an opportunity to dissociate TSLP inhibition from other non-desired activities. This study illustrates the potential of phenotypic drug discovery to complement target based approaches by providing new chemistry and biology leads.


Asunto(s)
Citocinas/antagonistas & inhibidores , Descubrimiento de Drogas , Pulmón/efectos de los fármacos , Células Cultivadas , Citocinas/biosíntesis , Células Epiteliales/efectos de los fármacos , Humanos , Pulmón/citología , Pulmón/metabolismo , Reacción en Cadena en Tiempo Real de la Polimerasa , Linfopoyetina del Estroma Tímico
5.
J Dermatol ; 30(4): 332-6, 2003 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-12707471

RESUMEN

We present the first reported case of disseminated cytomegalovirus (CMV) in association with prednisone therapy in bullous pemphigoid (BP). A 66-year-old black male patient was admitted to our hospital presenting cutaneous pruritic lesions represented by tense blisters, with serous content on the arms, abdomen and legs. Laboratory findings confirmed the diagnosis of BP. After two weeks of prednisone therapy, the patient developed prolonged fever, which was caused by CMV disseminated disease, with prompt clinical recovery after ganciclovir administration.


Asunto(s)
Infecciones por Citomegalovirus/complicaciones , Infecciones por Citomegalovirus/diagnóstico , Fiebre/complicaciones , Infecciones Oportunistas/complicaciones , Penfigoide Ampolloso/complicaciones , Prednisona/administración & dosificación , Anciano , Biopsia con Aguja , Infecciones por Citomegalovirus/tratamiento farmacológico , Fiebre/diagnóstico , Estudios de Seguimiento , Ganciclovir/administración & dosificación , Humanos , Huésped Inmunocomprometido , Inmunohistoquímica , Masculino , Infecciones Oportunistas/diagnóstico , Penfigoide Ampolloso/tratamiento farmacológico , Penfigoide Ampolloso/inmunología , Prednisona/efectos adversos , Medición de Riesgo , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA